Medicxi — 2018 Investments

2 investments dated 2018 · listed companies and verified rows first · show all

Xenikosxenikos.comSeries B · May 2018 · $30M

Xenikos was a clinical-stage biotech developing T-Guard, an immune-system "reset" therapy aimed at life-threatening immune conditions such as acute graft-versus-host disease, transplant rejection, and severe autoimmune diseases.

BiotechHealthtech

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Synthorx

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.